Show simple item record

dc.contributor.authorStepanova, DSen
dc.contributor.authorSemenova, Gen
dc.contributor.authorKuo, Y-Men
dc.contributor.authorAndrews, AJen
dc.contributor.authorAmmoun, Sen
dc.contributor.authorHanemann, COen
dc.contributor.authorChernoff, Jen
dc.date.accessioned2017-08-09T15:40:50Z
dc.date.available2017-08-09T15:40:50Z
dc.date.issued2017-07-20en
dc.identifier.urihttp://hdl.handle.net/10026.1/9709
dc.description.abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors in the central nervous system, most notably schwannomas and meningiomas. Mutational inactivation of the NF2 gene encoding the protein Merlin is found in most sporadic and inherited schwannomas, but the molecular mechanisms underlying neoplastic changes in schwannoma cells remain unclear. We report here that NF2-deficient cells display elevated expression levels of key enzymes involved in lipogenesis and that this upregulation is caused by increased activity of Torc1. Inhibition or knockdown of fatty acid synthase (FASN), the enzyme that catalyzes the formation of palmitic acid from malonyl-CoA, drove NF2-deficient cells into apoptosis. Treatment of NF2-mutant cells with agents that inhibit the production of malonyl-CoA reduced their sensitivity to FASN inhibitors. Collectively, these results suggest that the altered lipid metabolism found in NF2-mutant cells renders them sensitive to elevated levels of malonyl-CoA, as occurs following blockade of fatty acid synthase, suggesting new targeted strategies in the treatment of NF2-deficient tumors.

en
dc.language.isoenen
dc.titleAn essential role for the tumor suppressor Merlin in regulating fatty acid synthesis.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/28729415en
plymouth.publication-statusPublished onlineen
plymouth.journalCancer Researchen
dc.identifier.doi10.1158/0008-5472.CAN-16-2834en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dcterms.dateAccepted2017-07-13en
dc.rights.embargodate2018-07-20en
dc.identifier.eissn1538-7445en
dc.rights.embargoperiod12 monthsen
rioxxterms.versionofrecord10.1158/0008-5472.CAN-16-2834en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden
rioxxterms.licenseref.startdate2017-07-20en
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV